Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Ideal Thrombolytic Agent: GISSI‐2 and ISIS‐3

The Ideal Thrombolytic Agent: GISSI‐2 and ISIS‐3 Streptokinase (SK) and tissue plasminogen activator (alteplase (tPA)) are by far the most intensively studied thrombolytic agents, but only recently a direct head‐to‐head comparison (GISSI‐2 Trial, in which 12,490 patients have been randomized) has become available to the scientific community. This trial, with its international extension (the International tPA/SK Mortality Trial) recruited more than 20,000 patients, showed that the two drugs tested (SK and tPA) were substantially comparable as far as the clinical events were considered. ISIS‐3, the largest randomized clinical trial ever performed, compares SK, tPA, and APSAC in a factorial design. Its results will be available before spring, 1991. It is likely that these two studies, if the results will be consistent, will give a definitive answer about comparison among thrombolytic drugs. As a consequence of that achievement, the interest of the scientific community will possibly be directed towards the long‐term prevention of the infarct complications, namely ventricular remodeling and infarct expansion or life‐threatening arrhythmias. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

The Ideal Thrombolytic Agent: GISSI‐2 and ISIS‐3

Download PDF
11 pages

Loading next page...
 
/lp/wiley/the-ideal-thrombolytic-agent-gissi-2-and-isis-3-gW7RKtKenc

References (71)

Publisher
Wiley
Copyright
Copyright © 1990 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.1990.tb00976.x
Publisher site
See Article on Publisher Site

Abstract

Streptokinase (SK) and tissue plasminogen activator (alteplase (tPA)) are by far the most intensively studied thrombolytic agents, but only recently a direct head‐to‐head comparison (GISSI‐2 Trial, in which 12,490 patients have been randomized) has become available to the scientific community. This trial, with its international extension (the International tPA/SK Mortality Trial) recruited more than 20,000 patients, showed that the two drugs tested (SK and tPA) were substantially comparable as far as the clinical events were considered. ISIS‐3, the largest randomized clinical trial ever performed, compares SK, tPA, and APSAC in a factorial design. Its results will be available before spring, 1991. It is likely that these two studies, if the results will be consistent, will give a definitive answer about comparison among thrombolytic drugs. As a consequence of that achievement, the interest of the scientific community will possibly be directed towards the long‐term prevention of the infarct complications, namely ventricular remodeling and infarct expansion or life‐threatening arrhythmias.

Journal

Journal of Interventional Cardiology – Wiley

Published: Sep 1, 1990

There are no references for this article.